NM
Nello Mainolfi (Chief Executive Officer) filed 7 Form 4 reports in the trailing twelve months (0 purchases, 7 sales), most often in Kymera Therapeutics, Inc. (KYMR). The largest single filing was $9.2M of KYMR (80,000 sh across 5 lots, as filed), executed Jul 1. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
7
0 buys · 7 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$34.9M
shares × price, as filed
Last traded
Oct 1
Filed Oct 1
Median ADV $102.3M across their filed names
Open performance→Volume by month
Buys $0
Sells $39.7M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
7 filings
Sector per market data · by filing · past 12 months
Most traded names
KYMRRecent filings
KYMRSALE
Kymera Therapeutics, Inc.
View filing →
$1.5M30,000 sh × $49.00
Exec Sep 16 2025
Filed Sep 16 2025 · 5:30 PM ET KYMRSALE Kymera Therapeutics, Inc. View filing → $1.5M
30,000 sh × $49.00
Exec Jun 3 2025
Filed Jun 3 2025 · 5:30 PM ET